综述:非酒精性脂肪性肝病与心血管疾病的关联及治疗考量
本文综述NAFLD与心血管疾病的关联及治疗启示。NAFLD与高血压、动脉僵硬、动脉粥样硬化、冠心病、房颤及主动脉瓣硬化相关,进展期肝纤维化是预后关键因素。生活方式减重是管理基石,但药物管理亦重要,现有药物各有考量。
要点
- NAFLD与多种心血管疾病相关,进展期肝纤维化是心血管及全因死亡的关键预后因素。
- 生活方式减重是NAFLD和CVD管理基石,但难以实现和长期维持。
- 吡格列酮增加体重,心衰患者应避免;他汀不应避免用于有CVD风险的NAFLD患者。
核心结论
- NAFLD与心血管疾病相关,具有临床和治疗启示。
研究设计与样本
- 检索PubMed,证据主要来自荟萃分析,不足时依次使用临床试验和观察性研究。
主要发现
- NAFLD与动脉高血压、动脉僵硬、动脉粥样硬化、冠心病、心房颤动和主动脉瓣硬化相关。
- 进展期肝纤维化是终末期肝病及心血管和总体死亡率的关键预后因素。
- 通过生活方式(饮食和运动)减重是NAFLD和CVD管理的基石,但难以实现且可能更难长期维持。
关键数值与推荐
- 吡格列酮被多数指南推荐用于NASH,但增加体重,充血性心力衰竭患者应避免使用。
- 有CVD风险的NAFLD患者不应避免使用他汀类药物。
- GLP-1受体激动剂和SGLT-2抑制剂在NAFLD和CVD中显示有希望的结果,但需要更多硬终点研究。
- 奥贝胆酸对血脂谱有不良影响,应谨慎考虑。
临床怎么用
- 对有CVD风险的NAFLD患者,不应避免使用他汀类药物。
- 心衰患者应避免使用吡格列酮。
- 生活方式减重是NAFLD和CVD管理的基础,但需注意长期维持困难。
局限性
- 证据主要来自荟萃分析,部分领域数据不足时使用临床试验和观察性研究。
- GLP-1受体激动剂和SGLT-2抑制剂需要更多硬终点研究。
- 目前尚无获批的NAFLD药物治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are increasing data on the association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD). AIM: To summarise evidence on the association between NAFLD and CVD in the clinical setting and provide potential therapeutic implications. METHODS: We searched PubMed. Evidence was primarily derived from meta-analyses. and then, if data were insufficient, from clinical trials, and then from observational studies. RESULTS: NAFLD has been linked to arterial hypertension, arterial stiffness, atherosclerosis, coronary artery disease, atrial fibrillation and aortic valvular sclerosis. Advanced liver fibrosis is a crucial prognostic factor for end-stage liver disease and for cardiovascular and overall mortality. Weight loss through lifestyle modifications (diet and exercise) remains the cornerstone of the management of both NAFLD and CVD, but is difficult to achieve and possibly more difficult to sustain long term. Therefore, pharmacological management of NAFLD seems to be important, although no licenced medication currently exists. Pioglitazone, proposed for non-alcoholic steatohepatitis (NASH) by most guidelines, increases weight and should be avoided in congestive heart failure. Statins should not be avoided in NAFLD patients at risk for CVD. Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, two classes of anti-diabetic drugs, have shown promising results in NAFLD and CVD, but more studies with hard end points are needed. Obeticholic acid, a promising medication for NASH under investigation, should be carefully considered, owing to its adverse effect on lipid profile. CONCLUSIONS: NAFLD is associated with CVD, which may have certain clinical and therapeutic implications.
引用
- Polyzos SA, Kechagias S, Tsochatzis EA, et al. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther. 2021. PMID: 34416040. doi:10.1111/apt.16575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。